Maria Gałuszko-Węgielnik, Katarzyna Jakuszkowiak-Wojten, Alina Wilkowska, Wiesław Jerzy Cubała
{"title":"双相情感障碍伴边缘型人格障碍患者的短期氯胺酮治疗:重点是冲动性。","authors":"Maria Gałuszko-Węgielnik, Katarzyna Jakuszkowiak-Wojten, Alina Wilkowska, Wiesław Jerzy Cubała","doi":"10.1080/15622975.2023.2227901","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD.</p><p><strong>Methods: </strong>This case presents a female patient diagnosed with both Bipolar Disorder (BD) and Borderline Personality Disorder (BPD) who received intravenous ketamine treatment to alleviate acute depressive symptoms.</p><p><strong>Results: </strong>Initially, ketamine ameliorated depressed symptoms. However, as the ketamine treatment continued, the patient showed an increase in nonsuicidal self-injury (NSSIs) and impulsive conduct with a aggravation of dissociative symptoms. As a result, intravenous ketamine was discontinued, and the patient received the medication, which proved helpful.</p><p><strong>Conclusions: </strong>Although ketamine presents antidepressant properties, reports on its impact on emotional dysregulation and impulsive conduct are unclear and not alike to its antidepressant effect. Therefore, there is a need for more studies investigating the effectiveness and safety of this rapid-acting medicine in this patient population.</p>","PeriodicalId":49358,"journal":{"name":"World Journal of Biological Psychiatry","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity.\",\"authors\":\"Maria Gałuszko-Węgielnik, Katarzyna Jakuszkowiak-Wojten, Alina Wilkowska, Wiesław Jerzy Cubała\",\"doi\":\"10.1080/15622975.2023.2227901\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD.</p><p><strong>Methods: </strong>This case presents a female patient diagnosed with both Bipolar Disorder (BD) and Borderline Personality Disorder (BPD) who received intravenous ketamine treatment to alleviate acute depressive symptoms.</p><p><strong>Results: </strong>Initially, ketamine ameliorated depressed symptoms. However, as the ketamine treatment continued, the patient showed an increase in nonsuicidal self-injury (NSSIs) and impulsive conduct with a aggravation of dissociative symptoms. As a result, intravenous ketamine was discontinued, and the patient received the medication, which proved helpful.</p><p><strong>Conclusions: </strong>Although ketamine presents antidepressant properties, reports on its impact on emotional dysregulation and impulsive conduct are unclear and not alike to its antidepressant effect. Therefore, there is a need for more studies investigating the effectiveness and safety of this rapid-acting medicine in this patient population.</p>\",\"PeriodicalId\":49358,\"journal\":{\"name\":\"World Journal of Biological Psychiatry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Biological Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15622975.2023.2227901\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15622975.2023.2227901","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity.
Objectives: Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD.
Methods: This case presents a female patient diagnosed with both Bipolar Disorder (BD) and Borderline Personality Disorder (BPD) who received intravenous ketamine treatment to alleviate acute depressive symptoms.
Results: Initially, ketamine ameliorated depressed symptoms. However, as the ketamine treatment continued, the patient showed an increase in nonsuicidal self-injury (NSSIs) and impulsive conduct with a aggravation of dissociative symptoms. As a result, intravenous ketamine was discontinued, and the patient received the medication, which proved helpful.
Conclusions: Although ketamine presents antidepressant properties, reports on its impact on emotional dysregulation and impulsive conduct are unclear and not alike to its antidepressant effect. Therefore, there is a need for more studies investigating the effectiveness and safety of this rapid-acting medicine in this patient population.
期刊介绍:
The aim of The World Journal of Biological Psychiatry is to increase the worldwide communication of knowledge in clinical and basic research on biological psychiatry. Its target audience is thus clinical psychiatrists, educators, scientists and students interested in biological psychiatry. The composition of The World Journal of Biological Psychiatry , with its diverse categories that allow communication of a great variety of information, ensures that it is of interest to a wide range of readers.
The World Journal of Biological Psychiatry is a major clinically oriented journal on biological psychiatry. The opportunity to educate (through critical review papers, treatment guidelines and consensus reports), publish original work and observations (original papers and brief reports) and to express personal opinions (Letters to the Editor) makes The World Journal of Biological Psychiatry an extremely important medium in the field of biological psychiatry all over the world.